BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25734906)

  • 1. Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?
    Custers JA; Tielen R; Prins JB; de Wilt JH; Gielissen MF; van der Graaf WT
    Acta Oncol; 2015; 54(8):1202-8. PubMed ID: 25734906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors.
    Poort H; van der Graaf WT; Tielen R; Vlenterie M; Custers JA; Prins JB; Verhagen CA; Gielissen MF; Knoop H
    J Pain Symptom Manage; 2016 Aug; 52(2):265-71. PubMed ID: 27233141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden.
    Langenberg SMCH; Reyners AKL; Wymenga ANM; Sieling GCM; Veldhoven CMM; van Herpen CML; Prins JB; van der Graaf WTA
    Acta Oncol; 2019 Feb; 58(2):191-199. PubMed ID: 30280630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumors (GIST) related emergencies.
    Sorour MA; Kassem MI; Ghazal Ael-H; El-Riwini MT; Abu Nasr A
    Int J Surg; 2014; 12(4):269-80. PubMed ID: 24530605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
    Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
    Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
    Barrios CH; Blackstein ME; Blay JY; Casali PG; Chacon M; Gu J; Kang YK; Nishida T; Purkayastha D; Woodman RC; Reichardt P
    Eur J Cancer; 2015 Nov; 51(16):2423-33. PubMed ID: 26248685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
    J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
    Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
    Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
    Angelini S; Pantaleo MA; Ravegnini G; Zenesini C; Cavrini G; Nannini M; Fumagalli E; Palassini E; Saponara M; Di Battista M; Casali PG; Hrelia P; Cantelli-Forti G; Biasco G
    Pharmacol Res; 2013 Feb; 68(1):1-6. PubMed ID: 23127916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
    Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
    Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-reported cognitive impairments and quality of life in patients with gastrointestinal stromal tumor: Results of a multinational survey.
    Ferguson RJ; Manculich J; Chang H; Sareen NJ; Snitz BE; Terhorst L; Bovbjerg DH; Duensing AU
    Cancer; 2022 Nov; 128(22):4017-4026. PubMed ID: 36125989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical therapy of GIST; from palliative to curative treatment].
    Le Cesne A; Blay JY
    Bull Acad Natl Med; 2012; 196(4-5):861-74; discussion 874-76. PubMed ID: 23550449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM; Amand MS; Demetri GD
    Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.